• We investigate the effect of bone marrow mononuclear cells (BMMC) in ALS mice.
a b s t r a c t
Cell-based therapy provides a novel strategy to restore lost neurons or modulate the degenerating microenvironment in amyotrophic lateral sclerosis (ALS). This study verified the therapeutic potential of bone marrow mononuclear cells (BMMCs) in SOD1 G93A mice. BMMCs were obtained from enhanced green fluorescent protein (EGFP) transgenic C57BL/6 mice ( EGFP BMMCs) or from SOD1 G93A transgenic mice ( mSOD1 BMMCs) and given to mice at the pre-symptomatic or late symptomatic stage. Survival, body weight and motor performance data were recorded. DNA integrity was evaluated using the alkaline comet assay. The spinal cords were collected to assess motoneuron preservation and cell migration.
EGFP BMMCs and mSOD1 BMMCs transplantation to pre-symptomatic SOD1 G93A mice prolonged survival and delayed disease progression. The effects were more significant for the EGFP BMMC-transplanted mice. In late symptomatic mice, EGFP BMMCs promoted a discrete increase in survival, without other clinical improvements. DNA from EGFP BMMCs and mSOD1 BMMCs was found in the spinal cords of transplanted animals. DNA damage was not modified by BMMCs in any of the studied groups. Despite positive behavioral effects observed in our study, the limited results we observed for late transplanted mice call for caution before clinical application of BMMCs in ALS.
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Introduction
Cell therapy emerged as a promising approach to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). A number of strategies have been studied, such as the transplantation of genetically modified cells to secrete trophic factors [1] , human umbilical cord blood cells [2, 3] , neural stem cells [4] , iPSC-derived cells [5] , mesenchymal stem cells (MSC) [6] [7] [8] and other cellular populations of the bone marrow [9, 10] , including bone marrow mononuclear cells (BMMCs) [11] [12] [13] [14] . Nevertheless, the reported efficacy from clinical studies is still controversial [15] . Even if the procedure has been shown to be safe, more preclinical studies are required to determine the best cell source and dosage, the route of administration, the use of autologous or heterologous donors and the time of intervention.
It has been reported that BMMCs promote beneficial effects in pre-symptomatic or early symptomatic SOD1 mice [11] [12] [13] [14] 16] . However, the therapeutic potential of intravenously transplanted BMMCs in late symptomatic ALS mice remains unknown. Furthermore, additional studies are needed to clarify aspects related to the transplantation from mutant donors. To explore these possibilities, we intravenously injected SOD1 G93A mice with BMMCs from enhanced green fluorescent protein (EGFP) transgenic C57BL/6 mice or SOD1 G93A donors. Transplantation was performed in either pre-symptomatic or late symptomatic mice bearing the SOD1 G93A transgene.
Material and methods

Animals
B6SJL-Tg(SOD1-G93A)1Gur/J mice breeding pairs were purchased from the Jackson Laboratory (Bar Harbor, ME, EUA), and the offspring were genotyped as previously described [17, 18] . Transgenic EGFP + C57BL/6 mice were also used in this study. All animals were kept under 12-h light/dark cycle, 22-24 • C temperature and given free access to food and water. The Animal Care and Ethics Committee at PUCRS approved this study (09/00091). The experimental groups were balanced with regard to animal gender, age and body weight. Care was taken distributing littermates among the different experimental groups so that the number of copies of the mutant SOD1 gene would likely be similar.
BMMC preparation
BMMCs were obtained from EGFP + C57BL/6 or from SOD1 G93A male mice, as previously described [19] . Either EGFP or the Y chromosome was used as a reporter for the transplanted cells. BMMCs were incubated with conjugated antibodies against CD34, CD19, CD117, CD45 and Sca1. The labeled cells were collected and analyzed using a FACSCalibur cytometer.
BMMC transplantation
The mice were distributed into five experimental groups: (1) the EGFP BMMC-70 group: SOD1 G93A mice transplanted at 70 days (pre-symptomatic) with BMMCs from C57BL/6-EGFP mice (n = 15); (2) the mSOD1 BMMC-70 group: SOD1 G93A mice transplanted at 70 days (pre-symptomatic) with BMMCs from SOD1 G93A mice (n = 15); (3) the EGFP BMMC-110 group: SOD1 G93A mice transplanted at 110 days (late symptomatic) with BMMCSs from C57BL/6-EGFP mice (n = 15); (4) the mSOD1 BMMC-110 group: SOD1 G93A transplanted at 110 days (late symptomatic) with BMMCs from SOD1 G93A mice (n = 14); and (5) the SAL group: SOD1 G93A mice treated with saline (n = 23). EGFP BMMCs or mSOD1 BMMCs suspensions were prepared at a concentration of 1 × 10 7 , and injected via tail vein. An additional cohort of animals (n = 2 per transplantation group) received BMMCs as described above but was sacrificed at 24 h, 1 week or 2 weeks after transplantation, and tissue samples were collected for PCR. Other animal cohorts were treated as described and euthanized at 120 days for histological analysis (n = 5 per group) or for the alkaline comet assay (n = 4 per group).
Survival
Endpoint was determined as the age when the mouse was unable to right itself within 30 s when placed on its back in a supinated position, as previously described [10] .
Clinical evaluation
Body weight measurements were used to determine disease onset and the symptomatic stage. All mice were weighed weekly beginning on the 9th week. When the mice were 11 weeks old, they were weighed twice a week, and three times a week when the mice reached the age of 16 weeks, until the endpoint. All measurements were taken between 1 and 4 p.m. [20] . Disease onset was defined as the maximum weight recorded for each animal retrospectively. The animals were considered to have reached the symptomatic stage once they had lost 10% of their maximum weight [10] . The difference between the age at onset and the age at endpoint was used as a measure of disease progression.
Motor performance
Rotarod (EFF 412, Insight, Brazil) tests were conducted weekly from 11 weeks of age to endpoint. The mouse had up to seven minutes to remain in the rotating cylinder at 16 rpm. Mice were placed in the direction opposite to the rotation. The animals using paws to hold themselves to the cylinder for two consecutive laps were excluded. The latency until the mouse dropped from the cylinder was counted.
Polymerase chain reaction (PCR)
Nested PCR was used to identify the presence of BMMCs in the tissues of transplanted animals, as previously described [19] . To detect BMMCs from SOD1 G93A donors, who do not express EGFP, the samples were collected from female recipients, and the Y chromosome was detected. Tissue samples were collected from the spinal cord (dorsal root ganglions were removed from tissue), muscle, liver, spleen, lungs and heart at 1, 7 and 14 days after transplantation, and at endpoint. For EGFP DNA detection, groups were gender balanced.
Determination of DNA damage
To evaluate whether BMMCs prevent or mitigate the oxidative stress associated with the SOD1 G93A mutation [21] , the alkaline comet assay was performed. Samples of the spinal cord, muscle, cerebellum and cerebral cortex from the groups SAL, EGFP BMMC-70 and EGFP BMMC-110 were collected and processed, as previously described [22] .
Immunofluorescence
Transverse sections (20 m) of the lumbar spinal cord were incubated overnight with a primary rabbit anti-ChAT (choline acetyltransferase) antibody (1:500; Abcam, Cambridge, MA, USA). Alexa Fluor 568 goat anti-rabbit IgG (H + L) was used as secondary antibody (1:1.000; Invitrogen, Carlsbad, CA, USA). Glass coverslips were mounted with DAPI (4 ,6-diamidino-2-phenylindole) using Vectashield ® . Co-localization of DAPI with ChAT was analyzed using a confocal laser-scanning microscope (LSM 5 Exciter, Carl Zeiss, Germany) a Pro-Series High Performance CCD camera and Zen 5.0 software (Carl Zeiss, Inc.). Four serial sections were processed for each animal. The number of ChAT+ cells was calculated for each section, and the mean of the sections was used as an individual data for statistical analyses, as previously described [23] .
Statistics
The data are presented as the mean ± standard error of the mean. Kaplan-Meier survival curves and the log rank (Mantel-Cox) test were used to analyze survival, onset and symptomatic stage of disease. A two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test was used to analyze motor performance. Disease progression and motoneuron quantification were analyzed using one-way ANOVA followed by the Tukey post hoc test. Student's t-test was used for the alkaline comet assay. Analyses were performed using PrismGraph 5.0 software (Graph-Pad Software, San Diego, CA). A significance level of ␣ = 0.05 and p < 0.05 was applied to all tests.
Results
Survival is longer in pre-symptomatic or EGFP BMMC-treated mice
EGFP BMMC-70 mice survived approximately 20 days longer than SAL animals ( Fig. 1A ; p < 0.0001; 2 = 21.84) mSOD1 BMMC-70 mice also survived a mean of 11 days longer than SAL animals (p < 0.001; 2 = 11.27). However, comparing EGFP BMMC-70-and mSOD1 BMMC-70-treated animals, survival was longer in the mice receiving EGFP BMMC (p< 0.01; 2 = 7.8). The maximum observed survivals were 133 days for SAL animals, 150 days for mSOD1 BMMC-70 and 157 days for the EGFP BMMC-70-transplanted mice. Furthermore, we analyzed survival for SOD1 G93A mice treated at late symptomatic stage. Fig. 1B shows that mSOD1 BMMC did not improve the survival of mSOD1 BMMC-110 animals (p = 0.2586; 2 = 2.46). On the other hand EGFP BMMC-110 mice survived 5 days longer compared with SAL (p = 0.0117 and 2 = 6.36). The survival curves for presymptomatic or symptomatic EGFP BMMC transplantation, show that earlier treatment resulted in improved outcomes (p = 0.0271; 2 = 4.88, Fig. 1C ).
BMMCs delay onset and the symptomatic stage
In our colony, disease onset for SAL animals was observed around the 12th week (approximately 85 days). EGFP BMMC transplantation at 70 days delayed onset by approximately two weeks (p < 0.0001 vs. SAL, 2 = 26.37). For mSOD1 BMMC disease onset was delayed by one week (p < 0.0001 vs. SAL, 2 = 15.81). EGFP BMMC transplantation was more effective in delaying onset than mSOD1 BMMC (Fig. 2A, p < 0.05, 2 = 4.44) .
The onset of the symptomatic stage was observed at 15 week-old SAL mice. Both EGFP BMMC and mSOD1 BMMC delayed the symptomatic stage, but with more substantial results for EGFP BMMC transplantation (p = 0.047; 2 = 3.951; Fig. 2B ). Disease progression (the time elapsed from onset to endpoint) was 5.75 ± 0.27 weeks in SAL animals, 8.46 ± 0.46 weeks in EGFP BMMC-(p < 0.001 vs. SAL, Fig. 2C ) and 7.11 ± 0.38 weeks in mSOD1 BMMC-70 animals (p < 0.05 vs. SAL). There was significant difference between mSOD1 BMMC-70 and EGFP BMMC-70 animals (p < 0.05). EGFP BMMC-110 and mSOD1 BMMC-110 mice showed similar disease progression to SAL animals (Fig. 2D) . 3.3. EGFP BMMCs delay motor decline and preserve motor function in pre-symptomatic mice SAL mice first showed impaired motor function in the Rotarod test when they were 15 weeks old. mSOD1 BMMC-70 mice failed to complete the task at the same age. As Fig. 2E shows, EGFP BMMC-70 animals showed longer preservation of motor function, with significant motor decline observed on the 16th week. Furthermore, EGFP BMMC-70 animals continued to show better performance throughout the 15th, 16th and 17th week compared with the SAL group (p < 0.001) as well as weeks 15 and 17 compared with the mSOD1 BMMC-70 group (p < 0.05) mSOD1 BMMC-70 mice showed improved motor performance compared with SAL animals only at the 16th week (p < 0.01). The animals treated at late symptomatic stage first showed significant motor decline at the 15th week. As shown in Fig. 2F , neither EGFP BMMC nor mSOD1 BMMC restore motor function.
BMMC DNA was detected in samples from transplanted animals
Transplanted cells DNA was found in the spinal cord of animals at 24 h, 1 week and 2 weeks post-transplantation, and endpoint. In the liver, spleen, heart, lungs and muscle BMMC DNA was detected up to 2 weeks post-transplantation. At endpoint, BMMC DNA was found in the spleen and the muscle.
Damage to DNA integrity is not prevented or reversed after BMMC transplantation
To evaluate whether the more prominent beneficial effects of EGFP BMMC transplantation versus mSOD1 BMMC transplantation were due to modulation of oxidative stress, we performed the alkaline comet assay. However, we did not observe significant differences in DNA damage for any of the analyzed samples (Supplemental material).
Pre-symptomatic EGFP BMMC promotes motoneuron preservation
As shown in Fig. 3 , pre-symptomatic transplantation of EGFP BMMC was protective of motoneurons (p < 0.001 vs. SAL). However, the motoneuron counts after mSOD1 BMMC-70 treatment did not differ from those observed after SAL. No effect on motoneuron preservation was observed for 110-day-old treated animals for either treatment.
Discussion
Here, we show for the first time that intravenous transplantation of BMMCs prolonged the survival of late symptomatic SOD1 G93A mice. However, animals treated at earlier stages had better outcomes, and late treatment had no repercussion on motor function or motoneuron preservation. We also observed that even mSOD1 BMMCs had a therapeutic effect, but that it was less substantial than for cells from non-mutant donors. Although there might be a limitation to our study due to the fact that we used a narrow sample size considering our experimental groups were of mixed gender [24] , we minimized this limitation by balancing gender in the groups, and by characterizing overall lifespan in our colony, which is in accordance with the literature.
The positive outcomes observed in our study were associated with the presence of transplanted cells DNA in the spinal cord. We cannot determine from this data the location or whether the transplanted cells remained viable in the transplanted spinal cord. Nevertheless, DNA from transplanted cells was detected in the spinal cord at endpoint, but not in other tissues such as the liver, lungs and others. Intravenously injected cells migrate from the blood stream into injured sites in ALS models [3, 7, 10, [25] [26] [27] . Damage and leakage for both the blood/brain barrier and the blood/spinal cord barrier have been described in SOD1 mutant rodents [28] [29] [30] , and in sporadic ALS patients [31] . Garbuzova-Davis and colleagues found that blood/spinal cord barrier alterations in SOD1 animals and ALS patients share similarities, but that some pathogenic features such as pericyte degeneration, perivascular collagen IV expansion, and white matter capillary abnormalities are only observed in patients [31] . Although the complexity of barrier alterations in ALS patients is not fully understood yet, in animal models, the breakdown of the blood-spinal cord barrier seems to increase monocyte chemotactic protein-1 levels [6] . Cells expressing receptors to this cytokine migrate to spinal cord regions where there are neuronal loss and breakdown of the barrier [32] . Elevated levels of stem cell factor, a chemoattractant expressed by transgenic SOD1 mice, could contribute to chemotaxis into degenerating sites [33] . We also observed that BMMCs migrated and/or were trapped in the spleen, where they could interact with host cells and modulate the inflammatory cascade, as previously proposed [3] .
It has been reported that BMMCs prolong survival of ALS mice, delay motor function impairment and are neuroprotective [1, 7, [10] [11] [12] [13] 16, [33] [34] [35] . However, few studies compared the therapeutic potential of non-mutant-versus mSOD1-expressing cells. Investigating the differences between an autologous and an allogeneic bone marrow transplant is important because non-neuronal cells are involved in ALS pathophysiology [36, 37] . Boillee and collaborators reported that limiting mutant damage to non-neuronal cells slowed the disease course [38] . Thus, it is important determining whether the introduction of cells carrying the mSOD1 would be beneficial or deleterious to the patient.
Our data shows that mSOD1 BMMCs have a moderate effect on the clinical outcome. Conversely, it has been shown that intraperitoneal [12] , or intra-bone marrow mSOD1 BMMC [11] , as well as the intravenous administration of mSOD1 Lin-c-kit+ cells [10] do not change survival or motor parameters. None of these authors reported the presence of transplanted cells in the spinal cord of host mice. Conversely, Terashima and collaborators found less migration of mutant SOD1 bone marrow cells to the spinal cord when compared with wild-type ones [14] . Cellular migration appears to be fundamental for the observed outcomes. Additionally, a dosedependent response of stem cell treatment in ALS models has been demonstrated [3, 26, 39] .
Nonetheless, mSOD1 BMMCs demonstrate inferior therapeutic effects compared with EGFP BMMC. Both a beneficial effect, mediated by immunomodulation or trophic factor secretion, and a deleterious mSOD1-mediated effect on motoneurons might be present. It has been recently described that bone marrow cells from ALS patients show less migratory activity and reduced trophic factor expression [40, 41] . This set of data should be considered when planning a clinical trial using autologous bone marrow transplantation. The single experimental study using stem cells obtained from an ALS patient assessed only the dose-response effect [39] .
Another important aspect addressed here is the window for therapeutic intervention. We demonstrate here that BMMC prolonged survival in late symptomatic SOD1 G93A mice. However, the effect was restricted to EGFP BMMC transplantation and was not associated with motor or morphological improvements. In a recent study, Gubert et al. observed no difference in the animals' lifespan or in the disease progression when BMMCs were injected intraspinally in the symptomatic phase, but observed delayed loss of function only in presymptomatic mice [42] . Ohnishi and collaborators treated 12-week-old animals (84 days old) with an intra-bone marrow injection of BMMCs following irradiation [11] . These authors chose an early symptomatic stage where functional impairment is still mild [2, 43] . For comparison, we detected motor impairment only at the 15th week. To our knowledge, the only study that verified the potential of stem cell administration on late symptomatic animals shows a therapeutic effect mainly for MSC genetically modified cells to express neurogenin 1 [6] . The need to use retroviruses to genetically manipulate cells raises important safety concerns and impairs the application of this procedure to patients.
The mechanisms that underlie neuroprotection and improved behavior for stem cell transplantation in ALS models are not fully understood. Based on the different outcomes observed for EGFP + transplanted cells we analyzed whether this effect was mediated by the modulation of oxidative stress-related DNA damage. Although others have shown that stem cell transplantation modifies oxidative stress [7] , our results do not indicate the involvement of this mechanism. There is likely a group of mechanisms acting simultaneously, such as the induction of endogenous cell proliferation, secretion of trophic factors and modulation of the anti-inflammatory activity [8, 23, 44, 45] . Trophic factor secretion by transplanted cells in experimental ALS models has been extensively studied [46] . It has also been demonstrated that MSCs transplantation reduces microglial activation and the expression of tumor necrosis factor alpha (TNF␣) [7] , NOX-2 and COX-2 [33] . Other factors, such as the maintenance of glutamate transporter GLT1 (glutamate transporter 1) levels may participate [7, 14, 47] . Furthermore, cell-cell interactions between healthy donor cells and host degenerating neurons could also explain the observed therapeutic effects [38, 48] .
Conclusions
The data we obtained in this study are relevant to the design of future cell-therapy trials. We show that therapeutic benefits were strongest for non-mSOD1 BMMCs and early treatment. The limited survival improvement and the lack of other functional benefits should be taken into account if one wishes to design not preventive but therapeutic trials for symptomatic patients. The impact of mutant cell transplantation on these results is harder to assess in terms of autologous cell transplantation in patients. Further studies that evaluate the efficacy of cell populations from sporadic ALS sources will be important to elucidate these aspects.
